The role of N-acetyltransferase 2 polymorphism in the etiopathogenesis of inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 56, Issue 7, 2011, Pages 2073-2080

  Baranska, M ^a   Trzcinski, R ^a   Dziki, A ^a   Rychlik Sych, M ^a   Dudarewicz, M ^a   Skretkowicz, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Genetic polymorphism; Inflammatory bowel disease; NAT2

Indexed keywords

ACYLTRANSFERASE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CAUCASIAN; CONTROLLED STUDY; DNA EXTRACTION; ENTERITIS; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RISK;

EID: 79959727748     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-010-1527-4     Document Type: Article

References (52)

1. Cho JH, Abraham C. Inflammatory bowel disease genetics: NOD2. Annu Rev Med. 2007;58:401-416. (Pubitemid 46706523)
2. Dotan I, Mayer L. Immunopathology of inflammatory bowel disease. Curr Opin Gastroenterol. 2002;18:416-427.
3. Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol. 2008;14:2670-2677.
4. Cho J, Weaver C. The genetics of inflammatory bowel disease. Gastroenterology. 2007;133:1327-1339. (Pubitemid 47494470)
5. Stokkers PFC, Reitsma PH, Tytgat NJ, van Deventer SJH. HLA-DR and - DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut. 1999;45:395-401. (Pubitemid 29400716)
6. Pompeo F, Brooke E, Kawamura A, Mushtaq A, Sim E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics. 2002;3:19-30. (Pubitemid 34285236)
7. Ladero JM. Influence of polymorphic N-acetylotransferase on non-malignant spontaneous disorders and on response to drugs. Curr Drug Metab. 2008;9:532-537. (Pubitemid 352025184)
8. Rovito P, Morse P, Spinek K, et al. Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:69-74.
9. University of Louisville. Human NAT2 alleles (Haplotypes). University of Louisville, Department of Pharmacology and Toxicology. 2010. http://louisville.edu/medschool/pharmacology. Accessed 04 February 2011.
10. Hein DW, Doll M, Fretland A. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev. 2000;9:29-42. (Pubitemid 30062907)
11. Weizmann Institute of Science. The GeneCards human gene database. N-acetyltransferase 2 (arylamine N-acetyltransferase). 2010. http://www.genecards.org/cgi-bin/carddisp.pl?gene=NAT2. Accessed 04 February 2011.
12. Cascorbi N, Drakoulis J, Brockmoller A, Maurer K, Sperling K. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995;57:581-592.
13. McKay J, Hashibe M, Hung RJ. Sequence variations of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancer in central Europe. Cancer Epidemiol Biomarkers Prev. 2008;17:141-147.
14. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish bladder cancer study and meta-analyses. Lancet. 2005;366:649-659.
15. Cooper GS. N-acetyltransferase genotypes in relation to risk of developing systemic lupus erythematosus.J Rheumatol. 2004;31(1):76-80.
16. Borlak J, Reamon-Buettner SM. N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease. BMC Med Genet. 2006;7:58.
17. Rocha L, Garcia C, de Mendonça A. N-acetyltransferase (NAT2) genotype and susceptibility of sporadic Alzheimer's disease. Pharmacogenetics. 1999;9:9-15. (Pubitemid 29176718)
18. Batra J, Ghosh B. N-acetylotransferases as markers for asthma and allergic/atopic disorder. Curr Drug Metab. 2008;9:546-553. (Pubitemid 352025186)
19. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques. 1991;1(3):298-300.
20. Spurr NK, Gough AC. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin Chem. 1995;41:1864-1869.
21. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis. 1999;20:1125-1129.
22. Kiyohara C. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. J Epidemiol. 2000;10:349-360.
23. Kumagal S, Komada F, Kita T, Morinobu A. N-acetylotransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharmacol Res. 2004;21:324-329. (Pubitemid 38221979)
24. Lei D, Pan X, Guo C, Xu F. Relationship between polymorphism of N-acetyltransferase 2 and genetic susceptibility to laryngeal carcinoma. Zhonghua Zhong Liu Za Zhi. 2002;24:154-156.
25. Lilla C, Verla-Tebit E, Risch A, Jager B, Hoffmeister M. Effect of NAT1 and NAT2 genetic polymorphism on colorectal cancer risk associated with exposure to tabacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev. 2006;15:99-107.
26. Luszawska-Kutrzeba T. NAT2 genotype in children with bronchial asthma and other atopic diseases. Probl Ter Monitor. 1998;9:115-122.
27. Niewiński P, Orzechowska-Juzwenko K. Importance of genetically determined acetylation of drugs and xenobiotics in pathogenesis of neoplasmatic diseases. Pol Merk Lek. 1997;2:231-235.
28. Pawlik A, Ostanek L, Brzosko I, Gawroska-Szklarz B. Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2002;72:319-325.
29. Skrȩtkowicz K, Skrȩtkowicz J, Gawrońska-Szklarz B, Górnik W, Rychlik-Sych M, Sysa-Jȩdrzejowska A. Lack of association between arylamine N-acetylotransferase polymorphism and systemic sclerosis. Eur J Clin Parmacol. 2005;60:773-778. (Pubitemid 40394570)
30. Varzim G, Monteiro E, Silva R, Pinheiro C, Lopes C. Polymporphism of arylamince N-acetylotransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL (J Rhino-Laryngology). 2002;64:206-212.
31. Zhou W, Liu G, Thurston SW. Genetic polymorphisms in N-acetyltransferase- 2 and microsomal epoxide hydrolase, cumulative cigarette smoking and lung cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:15-21. (Pubitemid 34118308)
32. Rychlik-Sych M, Skrȩtkowicz J. Drug metabolism. Farm Pol. 2008;64:51-60.
33. Dyderski S, Grzymisławski M. Metabolism of drugs, 1. Basic metabolic reaction. Pol Merk Lek. 2005;106:446-452.
34. McFarland LV. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World Gastroenterol. 2008;14:2625-2629.
35. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Digest Dis. 2007;8:171-178.
36. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7-G17. (Pubitemid 38802113)
37. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-1233. (Pubitemid 20366527)
38. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994;35:950-954.
39. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology. 2006;130:1039-1046.
40. Herszenyi L, Miheller P, Tulassay Z. Carcinogenesis in inflammatory bowel disease. Dig Dis. 2007;25:267-269. (Pubitemid 350194181)
41. Machida H, Tsukamoto K, Wen C, Shikuwa S. Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetylotransferase 2 gene. World J Gastroenterol. 2005;11:4822-4837.
42. Mahid SS, Colliver DW, Crawford N. Characterization of N-acetyltansferase 1 and 2 polymorphism and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma. BMC Med Genet. 2007;8:28-34.
43. de Jong DJ, van der Logt EMJ, van Schaik A. Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase. Gut. 2003;52:547-551.
44. Hickman D, Sim E. N-acetyltransferase polymorphism composition of phenotype and genotype in humans. Biochem Pharmacol. 1991;42:1007.
45. Lin HJ, Han CY, Lin BK, et al. Ethic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1999;4:125-134. (Pubitemid 24210930)
46. Golka K, Prior V, Błaszkewicz M, Bolt HM. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett. 2002;128:229-241. (Pubitemid 34183465)
47. Gu J, Liang D, Wang Y, Lu C, Wu X. Effects of N-acetyltransferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res. 2005;581:97-104. (Pubitemid 40255898)
48. Ochs-Balcom HM, Wiesner G, Elston RC. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am J Epidemiol. 2007;166:246-254. (Pubitemid 47216806)
49. Schnakenberg E, Ehlers C. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patient. Clin Genet. 1998;53:396-402. (Pubitemid 28252105)
50. Barańska M, Skrȩtkowicz J. Genetic polymorphism of oxidation and acetylation in cancers of digestive system. Pol Merk Lek. 2009;152:145-147.
51. Gawrońska-Szklarz B. Influence of genetic factors on drug treatment efficacy and safety in cardiovascular diseases. Acta Angiol. 2003;9:1-15.
52. Chen M, Xia B, Guo Q, Li J, Ye M, Hu Z. N-acetyltransferase 2 slow acetylators genotype associated with adverse effects of sulphalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol. 2007;21:155-158. (Pubitemid 47061612)